Novartis sues Chinese firm over attempts to make generic heart failure drug
30-09-2021
Novartis and others in ‘unprecedented’ COVID-19 partnership
27-03-2020
Novartis tries to block generic versions of Gilenya, enforces new patent
30-01-2020
II.studio / Shutterstock.com
Switzerland-based Novartis has failed to convince the UK Intellectual Property Office (IPO) that a trademark applied-for by Boston Healthcare should not be registered.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Novartis, UKIPO, Boston Healthcare, trademark opposition, Emolite, Edomige, emollient, healthcare, UK Intellectual Property Office
